This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ultragenyx Pharmaceutical Inc.
Drug Names(s): KRN-23, UX023
Description: KRN23 is an anti-FGF23 fully human antibody. FGF23 is a fibroblast growth factor involved in phosphate metabolism. It is secreted by osteocytes in response to elevated calcitriol, and in the kidneys, decreases the expression of NPT2, a sodium-phosphate cotransporter in the proximal tubule. Hence, FGF23 decreases the reabsorption and increases excretion of phosphate.
Ultragenyx and Kyowa Hakko Kirin
In September 2013, Ultragenyx announced it has entered into a collaboration and license agreement with Kyowa Hakko Kirin (KHK) to develop and commercialize KRN23. Under the terms of the agreement, Ultragenyx and KHK will collaborate on the development of KRN23 for the US, Canada and European Union (EU), with Ultragenyx leading development effortsin the XLH indication and the parties sharing development costs. If KRN23 is approved, Ultragenyx and KHK will share commercial responsibilities and profits in the US and Canada, KHK will commercialize KRN23 in the EU and Ultragenyx will develop and commercialize KRN23 in Mexico, Central and South America. KHK will manufacture and supply KRN23 for clinical and commercial use globally.
In August 2015, Ultragenyx announced the amendment of their collaboration and license agreement with KHK. Under the terms of this collaboration and license agreement, Ultragenyx and KHK will collaborate on the...See full deal structure in Biomedtracker
Partners: Kyowa Hakko Kirin Co., Ltd.
Additional information available to subscribers only: